Liquidia Technologies Inc Total Liabilities
Liquidia Technologies Inc total liabilities. Based on the latest financial reports, Liquidia Technologies Inc (LQDA) has total liabilities worth $326.80 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Liquidia Technologies Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Liquidia Technologies Inc (2016–2025)
Total liabilities of Liquidia Technologies Inc from 2016 to 2025. This chart illustrates how Liquidia Technologies Inc's total liabilities have evolved over time, based on quarterly financial data.
Liquidia Technologies Inc Competitors by Total Liabilities
The table below lists competitors of Liquidia Technologies Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Copa Holdings S.A
F:C2H
|
Germany | €3.81 Billion |
|
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SHG:600332
|
China | CN¥47.87 Billion |
|
GRUPO SIM. S.A.B. B ADR/3
F:GSM
|
Germany | €11.85 Billion |
|
TUI AG
F:TUI1
|
Germany | €17.37 Billion |
|
Fujian Wanchen Biotechnology Co. Ltd
SHE:300972
|
China | CN¥7.34 Billion |
|
Jinneng Holding Shanxi Coal Industry Co Ltd
SHG:601001
|
China | CN¥7.96 Billion |
|
Cadence Bancorp
NYSE:CADE
|
USA | $47.29 Billion |
|
Badger Meter Inc
NYSE:BMI
|
USA | $315.29 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Liquidia Technologies Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Liquidia Technologies Inc.
Liquidity & Leverage Metrics
Liquidia Technologies Inc Total Liabilities Ratios Explained
Liquidia Technologies Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.63 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Liquidia Technologies Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Liquidia Technologies Inc (2016–2025)
The table below shows the annual total liabilities of Liquidia Technologies Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $283.19 Million | +85.04% |
| 2024-12-31 | $153.04 Million | +115.43% |
| 2023-12-31 | $71.04 Million | +83.20% |
| 2022-12-31 | $38.78 Million | +36.23% |
| 2021-12-31 | $28.46 Million | +0.06% |
| 2020-12-31 | $28.45 Million | -16.08% |
| 2019-12-31 | $33.89 Million | +10.30% |
| 2018-12-31 | $30.73 Million | -36.68% |
| 2017-12-31 | $48.54 Million | +81.57% |
| 2016-12-31 | $26.73 Million | -- |
About Liquidia Technologies Inc
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung diseas… Read more